Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Quentin M. Anstee, Alessandro Mantovani, Herbert Tilg, et al.
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 15, Iss. 7, pp. 425-439
Closed Access | Times Cited: 257

Showing 1-25 of 257 citing articles:

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 573
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 471
NAFLD and cardiovascular diseases: a clinical review
Philipp Kasper, Anna Martin, Sonja Lang, et al.
Clinical Research in Cardiology (2020) Vol. 110, Iss. 7, pp. 921-937
Open Access | Times Cited: 461
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 440
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 368
Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study
Hokyou Lee, Yong‐ho Lee, Seung Up Kim, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 10, pp. 2138-2147.e10
Closed Access | Times Cited: 364
Nonalcoholic Fatty Liver Disease and the Heart
Eric Stahl, Devinder S. Dhindsa, Suegene Lee, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 8, pp. 948-963
Closed Access | Times Cited: 334
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 287
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
Heart Failure and Liver Disease
Αndrew Xanthopoulos, Randall C. Starling, Takeshi Kitai, et al.
JACC Heart Failure (2018) Vol. 7, Iss. 2, pp. 87-97
Open Access | Times Cited: 234
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 232
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
Abdulrahman Ismaiel, Dan L. Dumitraşcu
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 152
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas, Arturo Santos, Juan Armendáriz‐Borunda
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11629-11629
Open Access | Times Cited: 145
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Eda Kaya, Yusuf Yılmaz
Journal of Clinical and Translational Hepatology (2021) Vol. 10, Iss. 2, pp. 329-338
Open Access | Times Cited: 118
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 86
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 80
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 54
The Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Joscha Vonderlin, Triantafyllos Chavakis, Michael H. Sieweke, et al.
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 15, Iss. 6, pp. 1311-1324
Open Access | Times Cited: 44
Treating NASH by targeting peroxisome proliferator-activated receptors
Bart Staels, Laura Butruille, Sven Francque
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1302-1316
Open Access | Times Cited: 44
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
Michael Cooreman, Javed Butler, Robert P. Giugliano, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 20
A combined analysis of TyG index, SII index, and SIRI index: positive association with CHD risk and coronary atherosclerosis severity in patients with NAFLD
Wenyuan Dong, Yu-Xin Gong, Jianqi Zhao, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 17
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yao Yu, Jingjing Cai, Zhi‐Gang She, et al.
Advanced Science (2018) Vol. 6, Iss. 4
Open Access | Times Cited: 149
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 130
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Valerio Rosato, Mario Masarone, Marcello Dallio, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 18, pp. 3415-3415
Open Access | Times Cited: 116
Association between non‐alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta‐analysis
Alessandro Mantovani, Marco Dauriz, Damiano Sandri, et al.
Liver International (2019) Vol. 39, Iss. 4, pp. 758-769
Open Access | Times Cited: 106
Page 1 - Next Page

Scroll to top